topotecan has been researched along with Infection in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldwasser, F; Gross-Goupil, M; Hasbini, A; Lokiec, F; Lopez, G; Misset, JL; Romain, D; Tigaud, JM | 1 |
| Centurioni, R; Corvatta, L; Leoni, F; Leoni, P; Malerba, L; Marconi, M; Masia, MC; Mele, A; Offidani, M; Scortechini, A | 1 |
2 trial(s) available for topotecan and Infection
| Article | Year |
|---|---|
Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Synergism; Female; Fever; Humans; Infections; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Patient Dropouts; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Bone Marrow Diseases; Burkitt Lymphoma; Comorbidity; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Carriers; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, T-Cell; Life Tables; Liposomes; Male; Methotrexate; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Safety; Survival Analysis; Topotecan; Treatment Outcome | 2003 |